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To investigate the effect of menarche, pregnancies, and breastfeeding on the risk of developing
multiple sclerosis (MS) and disability accrual using a multivariate approach based on a large
prospective cohort of patients with clinically isolated syndrome (CIS).
Methods
A cross-sectional survey of the reproductive information of female participants in a CIS cohort
was performed. We examined the relationship of age at menarche with the risk of clinically
definite MS (CDMS), McDonald 2010 MS, and Expanded Disability Status Scale (EDSS)
3.0 and 6.0. The effect of pregnancy (before and after CIS) and breastfeeding in the risk of
CDMS, McDonald 2010 MS, and EDSS 3.0 was also examined. Univariate and multivariate
analyses were performed and findings were confirmed using sensitivity analyses and a pro-
pensity score model.
Results
The data of 501 female participants were collected. Age at menarche did not correlate with age
at CIS and was not associated with the risk of CDMS or EDSS 3.0 or 6.0. Pregnancy before CIS
was protective for CDMS in the univariate analysis, but the effect was lost in the multivariate
model and did not modify the risk of EDSS 3.0. Pregnancy after CIS was protective for both
outcomes in univariate and multivariate analyses when pregnancy was considered a baseline
variable, but the protective effect disappeared when analyzed as a time-dependent event.
Breastfeeding did not modify the risk for the 3 outcomes.
Conclusions
These results demonstrate that menarche, pregnancies, and breastfeeding did not substantially
modify the risk of CDMS or disability accrual using a multivariable and time-dependent
approach.
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de Colombia, Medelĺın, Colombia; Raul Carrea Institute for Neurological Research (L.N., X.M.), FLENI, Buenos Aires, Argentina; and Division of Neurology (X.M.), St. Michael’s Hospital,
University of Toronto, Canada.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing
Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e1507
Consistent data show that women worldwide are at higher
risk for multiple sclerosis (MS), with an incidence sex ratio
of 2:1, which increased over the last 2 decades.1 However,
there is conflicting evidence on the role of sex in MS prog-
nosis. Large natural history studies reported a longer time
from clinically isolated syndrome (CIS) to second attack and
secondary progressive MS in women compared to men.2,3
However, other studies did not observe a protective role of
female sex for the risk of second attack and only a mild effect
in MS prognosis using a multivariate analysis.4
The increased MS risk in women suggests differences in the
immune system or CNS between women and men, which
may be caused by genetic dissimilarities, sex hormones, and
environmental exposures. Nonhormonal factors may include
smoking, history of Epstein-Barr virus infection, vitamin D
deficiency, high body mass index (BMI), and high sodium
intake.5–8 Regarding hormonal factors, previous studies dem-
onstrated that women with MS exhibited younger age at
menarche compared to healthy controls,9 and an earlier men-
arche was associated with a younger age at CIS.10
The short-term effect of pregnancy has been studied pre-
viously; results demonstrate that relapse risk decreases during
pregnancy, but increases during the postpartum period due
to hormonal changes occurring during these periods.11,12
However, the role of pregnancy and breastfeeding in the long-
term prognosis of MS remains controversial.
We initiated the BARCELONA MS&GENDER project to
elucidate the role of hormonal factors in the modulation of
MS prognosis. The present substudy investigated the role of
menarche, pregnancies, and breastfeeding in MS prognosis.
Methods
Study design
This study was an observational study based on an ongoing
prospective CIS cohort. This cohort began in 1995 and
includes patients aged <50 years who exhibited a CIS sugges-
tive of CNS demyelination not attributable to other dis-
eases with symptom onset within 3 months of the first clinical
evaluation. Clinical, demographic, CSF, andMRI information
were prospectively collected using a prespecified protocol.
Brain MRIs were performed at baseline and were repeated
after 12 months and every 5 years thereafter. A baseline spinal
cord MRI was only performed when patients presented
with spinal cord syndrome from 1995 to 2006, but these
data were collected for all patients with CIS beginning in
2007. The patients were seen on a regular basis for clinical
evaluation, which included Expanded Disability Status Scale
(EDSS) evaluation and relapses. The patients who did not
attend 2 consecutive follow-up visits were defined as lost
to follow-up.4
Female patients from the previously described cohort were
invited to participate in the MS Gender Project. Their
clinical, demographic, CSF, and MRI data were obtained
from the prospectively collected data within the cohort.
These patients also completed a self-administered survey
that retrospectively collected reproductive information, ex-
ternal hormonal exposures, and other environmental risk
factors (variables described in table 1). Participants were also
asked to report their body size self-perception by selecting
1 of 9 body silhouettes on the Stunkard figure rating scale13
at the age of menarche and CIS, ranging from very thin to
extremely obese, which is a accepted as a proxy of measure
for BMI.
The survey was completed from February 2015 until No-
vember 2015 during the participants’ regular clinical assess-
ments using a tablet device or a printed version or via email
with the patient’s consent. An invitation to participate with
the link to access the survey online was sent. A reminder email
was sent up to 3 times if the patient did not fill out the survey
after the first email invitation. Any missing or ambiguous data
were confirmed during clinical visits or telephone. This
survey was validated in nonmedical field women and re-
quired 5–10 minutes to complete.
Descriptive statistics were obtained for the demographic,
clinical, CSF, and MRI variables and specific reproductive
information (i.e., age at menarche, pregnancies, and breast-
feeding). Spearman correlation examined the relationships
of age at menarche with age at CIS and age at menarche with
age at MS. Given that a different disease onset (multifocal
or with encephalopathy) and evolution with high frequency
of relapses in the first few years was described for pediatric-
onset MS,14 a separate analysis of age at menarche was per-
formed in the group of female participants who experienced
their CIS before age 18.
The effect of menarche on the time to CIS for the studied
outcomes CDMS, McDonald 2010, EDSS 3.0 and 6.0) was
evaluated using a Cox regression analysis adjusted by age at CIS,
topography, oligoclonal bands (OB),MRI, treatment, and body
size at age at menarche. Confounders were selected based on
the results of the studies previously performed in the same
Glossary
aHR = adjusted hazard ratio; BMI = body mass index; CDMS = clinically definite multiple sclerosis; CI = confidence interval;
CIS = clinically isolated syndrome; DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; HR =
hazard ratio; MS = multiple sclerosis; OB = oligoclonal bands.
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cohort.4 A subgroup analysis compared the age at menarche
between 2 different prognostic profile groups (high-risk and
low-risk female participants). The high-risk group (CIS-
CDMS) included female participants who had an abnormal
baseline MRI and positive OB and presented with a second
attack during the follow-up. The low-risk group (CIS-CIS)
included female participants who had a normal baseline
MRI, negative OB, and no second attack during the fol-
low-up.
The effect of pregnancy (before and after CIS) on the time to
CDMS, McDonald 2010 MS, and EDSS 3.0 and 6.0 was
evaluated using a Cox regression analysis. Pregnancy after
CIS was analyzed using 2 methods. First, we used a dichoto-
mic variable that classified female participants who experi-
enced pregnancy or not at any time during follow-up, and
exposure to pregnancy was considered present from baseline.
Univariate and multivariate Cox models adjusted by age at
CIS, topography, OB, MRI, and disease-modifying treatment
(DMT) prior to a second attack (as a time-dependent vari-
able) were obtained. Second, we introduced pregnancy and
breastfeeding into the model as time-dependent covariates.
A woman was considered nonexposed to pregnancy until
the moment of delivery and exposed after pregnancy (until
outcome fulfilment or censored). Hazard ratio (HR) was
interpreted as the excess or shortage of risk of the studied
outcomes (CDMS, McDonald 2010 MS, EDSS 3.0 and 6.0)
for 2 female participants with the same follow-up time from
CIS in this second analysis. Finally, we confirmed our findings
by fitting a propensity score model for pregnancy at any time
using inverse probability weighting. These models controlled
for selection bias because participants who became pregnant
could exhibit different prognoses. Weights calculated after
fitting a logistic model to estimate the probability of becoming
pregnant over follow-up included age, previous pregnancy,
topography, OB, MRI lesions, DMT, and CDMS before
pregnancy.
The effect of breastfeeding on the time to CDMS, McDonald
2010 MS, and EDSS 3.0 was evaluated using Cox regression
analysis with a 3-categorical variable: nonpregnancy (reference
category), pregnancy without breastfeeding, and pregnancy
with breastfeeding. First, we used a variable that classified
participants who were breastfeeding or not at any time during
follow-up, and exposure to breastfeeding was considered
present from baseline. Univariate and multivariate Cox models
adjusted by age at CIS, topography, OB, MRI, and DMT
prior to a second attack (as a time-dependent variable) were
obtained. Second, we introduced breastfeeding into the model
as a time-dependent covariate. A woman was considered
nonexposed to breastfeeding until the moment of breast-
feeding and exposed thereafter (until outcome fulfilment or
censored). HR was interpreted as the excess or shortage of
risk of the studied outcomes for 2 women with the same
follow-up time from CIS in this second analysis.
Sensitivity analyses were performed using the calculated
conception date (delivery date minus 9 months), and preg-
nancy and abortion after CIS were considered.
Standard protocol approvals, registrations,
and patient consents
This study was performed with the approval of the Ethics
Committee of Hospital Universitari Vall d’Hebron. All patients
signed a written informed consent form from the inclusion in
the ongoing CIS cohort.
Data availability
Anonymized data will be shared by request from any qualified
investigator.
Results
A total of 1,196 patients were enrolled in the prospective
CIS cohort study from January 1995 to November 2015.
Sixty-nine (6.1%) patients did not meet the general inclusion
criteria of the cohort and were excluded (exceeded entry
window, previous attack, age over 50 years, and alternative
diagnosis).
The female/male ratio of the remaining 1,127 patients was
2:1, of which 771 (68.4%) were female. A total of 501 female
participants completed the survey (65% return rate). Patients
who filled out the survey had a similar age at CIS (31.1 vs 31
years, p = 0.84) but were more prone to exhibit an abnormal
baseline MRI (82% vs 59%, p < 0.005), were more frequently













Body composition at menarche and CIS
25OH vitamin D at CIS
Cotinine levels at CIS
Abbreviations: CDMS = clinically definite multiple sclerosis; CIS = clinically
isolated syndrome.
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on DMT (53% vs 16%, p < 0.005), and had a longer follow-up
(9.5 vs 5.3 years, p < 0.005). During follow-up, a total of 53%
of patients had a second attack; 61% met the McDonald 2010
MRI MS criteria, 13.4% reached confirmed EDSS 3.0, and
2.6% EDSS 6.0 (table 2).
Menarche
The mean age at menarche was 12.5 years (SD 1.62), and
the time from menarche to CIS was 18.5 (SD 8.0) years.
Comparisons of demographic, clinical, and MRI data between
patients with age at menarche before or after age 12.5 years
revealed that the only significant difference was the time
from menarche to CIS (18.5 vs 19.7 years, p = 0.001). This
difference was explained by the difference in age at menarche
but not by the difference in age at CIS (30.9 vs 31.9 years, p =
0.62). We performed correlation tests between the age at
menarche and age at CIS to further confirm this observation
and found no significant correlations (p = 0.94) between age at
menarche and age at CDMS (p = 0.6) or EDSS 3.0 (p = 0.2).
Age at menarche was also not related to the risk of second
attack (HR 1.03, 95% confidence interval [CI] [0.81–1.31],
p = 0.828), McDonald 2010 MS (HR 0.93, 95% CI
[0.74–1.16], p = 0.513), or disability accrual (EDSS 3.0 HR
1.09, 95%CI [0.67–1.77], p = 0.728; EDSS 6.0 HR 0.60, 95%
CI [0.20–1.85], p = 0.377), even after adjusting for age at CIS,
topography, OB, MRI, treatment, and body size at menarche
(table 3). Subgroup analysis comparing the age at menarche
between the high-risk (CIS-CDMS n = 181) and low-risk
(CIS-CIS n = 68) group revealed no significant differences
(p = 0.281).
A separate analysis of female participants with CIS under the
age of 18 years (n = 16) demonstrated that the mean age at
CIS was 15.8 (SD 1.3) years. The age at menarche in this
subgroup was 12.3 (SD 1.2) years, which was not different
from female participants with CIS after 18 years of age (12.3
vs 12.5, p = 0.55). None of these patients had CIS before
menarche, including the youngest patient at CIS, who was 12
years old. She experienced her menarche at 11 years of age.
Eleven (68.8%) patients had a second attack after a median of
12.2 (1.54–122) months. Thirteen (81%) girls met McDo-
nald 2010MS after a median of 12.1 (1.54–179) months. One
patient reached EDSS 3.0 36 months after the CIS.
Pregnancy
A total of 302 (60%) of the 501 female participants who filled
out the survey had at least one pregnancy prior to a CIS or
during follow-up. Comparison of nulliparous female partic-
ipants vs female participants with at least one pregnancy
demonstrated that nulliparous women exhibited CIS at
a younger age (28 vs 33 years, p < 0.005), had higher lesion T2
load in the basal MRI (10 vs 7, p = 0.02), and were more
frequently on DMT (62.1% vs 49.3%, p < 0.005).
Pregnancy prior to CIS
A total of 191 (38%) female participants had at least one
pregnancy prior to their CIS, and the mean age at CIS in this
group was 37 years. Univariate analysis revealed that pregnancy
prior to CIS was highly protective for CDMS (HR 0.62, 95%
CI 0.47–0.80, p < 0.001) and McDonald 2010 MS (HR 0.68,
95% CI 0.53–0.86, p = 0.001). This effect was lost in the
multivariate analysis when adjusting for age at CIS, topography,
Table 2 Patient characteristics
Baseline characteristics Values
Age at CIS, y, mean (SD) (n = 492) 31.1 (7.8)
Age at menarche, y, mean (SD) (n = 501) 12.5 (1.6)
Time from menarche to CIS, y, mean (SD) (n = 492) 18.5 (8)
Initial symptom, n (%)
Optic neuritis 160 (32)
Myelitis 147 (30)
Brainstem syndrome 135 (26)
Other 59 (12)
Oligoclonal bands, n (%) n = 428
Positive 273 (64)
Negative 155 (36)





Gadolinium enhancement, median (P25–P75) 0 (0–1)
Barkhof criteria, n (%) n = 489
0 Barkhof criteria 158 (32)
1–2 Barkhof criteria 108 (22)
3–4 Barkhof criteria 223 (46)
On DMT, n (%) 265 (23)





CDMS during follow-up, n (%) 267 (53)
McDonald MS during follow-up, n (%) 306 (61)
EDSS 3.0 during follow-up, n (%) 67 (13)
EDSS 6.0 during follow-up, n (%) 13 (2.5)
Abbreviations: CDMS = clinically definitive multiple sclerosis; CIS = clinically
isolated syndrome; DMT = disease-modifying treatment; EDSS = Expanded
Disability Status Scale; MS = multiple sclerosis.
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OB, MRI, and DMT for CDMS (adjusted HR [aHR] 1.09,
95% CI 0.79–1.51, p = 0.589) and McDonald 2010 MS (aHR
1.24, 95% CI 0.91–1.69, p = 0.17). Pregnancy prior to CIS did
not modify the risk of attaining confirmed EDSS 3.0 in the
univariate (HR 1.05, 95%CI 0.6–1.7, p = 0.837) ormultivariate
(aHR 1.3, 95% CI 0.7–2.7, p = 0.392) analyses.
Pregnancy after CIS
A total of 142 (28%) women had at least one pregnancy after
the CIS, and the mean age at CIS in this group was 27 years.
Univariate analysis revealed a protective effect of pregnancy for
CDMS (HR 0.30, 95% CI 0.20–0.46, p < 0.001), McDonald
2010 MS (HR 0.22, 95% CI 0.14–0.35, p < 0.001), and con-
firmed EDSS 3.0 (HR 0.43, 95% CI 0.24–0.80, p = 0.0073).
Multivariate analyses using pregnancy as a baseline variable
revealed that the protective effect persisted for CDMS (aHR
0.25, 95% CI 0.16–0.38, p < 0.001), McDonald 2010 MS
(aHR 0.23, 95% CI 0.14–0.37, p < 0.001), and disability
accrual (aHR 0.45, 95% CI 0.23–0.89, p = 0.008). However,
the protective effect disappeared for CDMS (aHR 1.13, 95%
CI 0.70–1.82, p = 0.6), McDonald 2010 MS (HR 1.01, 95%
CI 0.60–1.73, p = 0.90), and confirmed EDSS 3.0 (HR 0.89,
95% CI 0.44–1.80, p = 0.97) when pregnancy was analyzed
as a time-dependent event. We could not conduct the survival
analysis for EDSS 6 given that none of the pregnant women
after CIS reached EDSS 6 over follow-up. These results in-
dicate that the moment at which a woman becomes pregnant
did not affect the development of the 3 outcomes.
Propensity score analysis confirmed these results for CDMS
(aHR 1.14, 95% CI 0.63–2.06, p = 0.66), McDonald 2010 MS
(HR 1.71, 95% CI 0.88–3.33, p = 0.24), and EDSS 3.0 (aHR
1.03, 95% CI 0.43–2.50, p = 0.94) (figure 1).
Breastfeeding
For the 133 pregnancies that occurred after the CIS but
before EDSS 3.0, 87 female participants breastfed. Differ-
ences in the risk of CDMS, McDonald 2010 MS, and EDSS
3.0 were compared to patients who became pregnant and did
not breastfeed as a reference. No differences were observed
between breastfeeding and nonbreastfeeding groups for all
3 outcomes. The observed HRs were 1.41 (95% CI 0.61–3.23,
p = 0.42) for CDMS, 1.42 (95% CI 0.5–3.67, p = 0.46) for
McDonald 2010 MS, and 1.21 (95% CI 0.37–3.93, p = 0.75)
for EDSS 3.0.
Multivariate analyses of breastfeeding vs nonbreastfeeding
groups revealed that no significant differences remained, but
the direction of a marginal effect of breastfeeding appeared
(CDMS: aHR 0.92, 95% CI 0.39–2.14, p = 0.84; McDonald
2010: aHR 0.73, 95% CI 0.27–1.96, p = 0.53; and EDSS 3.0:
aHR 0.85, 95% CI 0.25–2.84, p = 0.79).
Table 3 Cox regression analysis for age at menarche and clinically definitive multiple sclerosis (CDMS), McDonald 2010
MS, and Expanded Disability Status Scale (EDSS) 3.0 and 6.0
HR 95% CI p Value aHRa 95% CI p Value
Time to CDMS
Age at menarche, y
<12.5 1.0 (Ref) 1.0 (Ref)
≥12.5 1.03 0.81–1.31 0.828 0.94 0.74–1.21 0.651
Time to McDonald 2010
Age at menarche, y
<12.5 1.0 (Ref) 1.0 (Ref)
≥12.5 0.93 0.74–1.16 0.513 0.89 0.70–1.12 0.327
Time to EDSS 3.0
Age at menarche, y
<12.5 1.0 (Ref) 1.0 (Ref)
≥12.5 1.09 0.67–1.77 0.728 1.15 0.70–1.92 0.579
Time to EDSS 6.0
Age at menarche, y
<12.5 1.0 (Ref) 1.0 (Ref)
≥12.5 0.60 0.20–1.85 0.377 0.60 0.19–1.90 0.383
Abbreviations: aHR = adjusted hazard ratio for the multivariate model; CI = confidence interval; HR = hazard ratio; OB = oligoclonal bands.
a Adjusted by age at clinically isolated syndrome, topography, OB, MRI, disease-modifying treatment, and body size at menarche.
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Analysis of breastfeeding as a time-dependent event revealed
that no significant differences remained for CDMS (aHR
1.09, 95% CI 0.47–2.54, p = 0.84) or McDonald 2010 MS
(HR 0.86, 95% CI 0.32–2.29, p = 0.77) and confirmed the
EDSS 3.0 result (HR 0.97, 95% CI 0.29–3.26, p = 0.97)
(figure 2). These results were confirmed in the sensitivity
analyses, which considered new T2 lesions during follow-up
and time to CDMS (CDMS: HR 1.10, 95% CI 0.47–2.59, p =
0.83; McDonald 2010: aHR 0.54, 95% CI 0.20–1.45, p = 0.22;
EDSS: HR 0.74, 95% CI 0.21–2.59, p = 0.64).
Discussion
The effect of hormonal changes during the female re-
productive life in the short and long term prognosis of MS
have been previously addressed.
Regarding menarche, the evidence of the effect of age at
menarche on age at MS onset and the risk and prognosis of MS
is inconclusive. It is known that puberty encompasses several
years and begins in girls between 8 and 12 years. Menarche
represents the end of puberty and is regulated by genetic and
Figure 1 Effect of pregnancy after clinically isolated syn-
drome (CIS) on the time to clinically definite
multiple sclerosis (CDMS), McDonald 2010 MS,
and Expanded Disability Status Scale (EDSS) 3.0
CI = confidence interval; HR = hazard ratio; OB = oligoclonal bands. *Adjusted by
age at CIS, topography, OB, MRI, and disease-modifying treatment prior to a sec-
ond attack (as a time-dependent variable). **Adjusted by age at CIS, topography,
OB, MRI, and disease-modifying treatment prior to a second attack (as a time-
dependentvariable)andpregnancyasa time-dependent covariate. ***Propensity
score model for pregnancy at any time using inverse probability weighting.
Figure 2 Effect of breastfeeding on the time to clinically
definite multiple sclerosis (CDMS), McDonald
2010 MS, and Expanded Disability Status Scale
(EDSS) 3.0
CI = confidence interval; HR = hazard ratio; OB = oligoclonal bands. *Adjusted
by age at clinically isolated syndrome (CIS), topography, OB, MRI, and disease-
modifying treatment prior to a second attack (as a time-dependent varia-
ble).**Adjusted by age at CIS, topography, OB, MRI, and disease-modifying
treatment prior to a second attack (as a time-dependent variable) and
breastfeeding as a time-dependent covariate.
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several environmental factors (BMI, diet, and exercise).15,16 It
has been hypothesized that early menarche or earlier sexual
maturation will involve more prolonged exposure to sexual
hormones, which might be related to an increased risk ofMS. A
Canadian study reported an increased risk of MS in women
with a younger age at menarche—menarche in controls oc-
curred at 12.6 years compared to 12.4 years in patients withMS
(p = 0.00017)—but did not find any association between age at
menarche and age at MS onset.9 Our study did not include
controls and cannot address this specific question; however, we
did not find a relationship between age at puberty and age at
MS onset or long-term clinical course of the disease (risk of
second attack, McDonald MS, risk of disability) even after
controlling for age at CIS, topography, OB, MRI, treatment,
and body size self-perception at menarche. A complementary
subgroup analysis comparing the high-risk group (CIS-CDMS)
and the low-risk group (CIS-CIS) did not observe differences
in the age at menarche and age at CIS.10
A separate analysis of the female participants in our cohort
with a CIS before the age of 18 years was performed. None of
these patients with pediatric onset had their CIS before
menarche, and the age at menarche was not different from the
rest of the group. However, a selection bias cannot be ex-
cluded because patients under the age of 12 years were likely
underrepresented in our cohort. Another potential limitation
of our study is recall bias because the age of menarche was
collected retrospectively. Womenmay remember the year but
not the exact date of the menarche; however, previous studies
demonstrated good reliability of the approximated age at
menarche.17 This should be taken into account since the
previous studies reported significant differences based on
a very small difference (months) of onset of menarche be-
tween the groups.9 It is therefore difficult to establish a causal
relationship between that small difference in age at menarche
reported in previous studies and the risk of such a complex
disease as MS. To overcome this limitation in the future, we
have started to collect this information prospectively.
The effect of pregnancy on the risk and evolution of MS has
been widely studied. Previous evidence supports a protective
effect of pregnancies on risk and short-term prognosis, de-
creasing clinical inflammatory activity, especially during the
last trimester.20,21
Higher parity has been associated with a decreased risk of
having a first clinical demyelinating event18,19 and pregnancy
was associated with a decreased risk of disability progression
(EDSS 6.0) compared to a nulliparous status.20–24 The pro-
tective effect of pregnancy after CIS on long-term outcomes
was recently addressed in a very large real-life cohort
(MSBase). This study considered pregnancy as a baseline and
not a time-dependent variable and found that female partic-
ipants with at least one pregnancy exhibited a lower EDSS
score over 10 years after a propensity score adjustment.25 In
contrast, this protective long-term effect was not found in
other studies that examined the possible association between
parity and the risk of disability accrual or secondary pro-
gressive MS.26,27 However, none of these studies considered
the interaction of other known confounding factors, such as
age at CIS, CIS topography, OB, burden of T2 lesion, and the
use of DMT.
Postpartum is a critical time for women with MS. The pro-
tective effect of pregnancy is lost, and mothers must decide
whether to restart early treatment or breastfeed.28 Some
studies suggested that breastfeeding modestly reduces the risk
of postpartum relapses29–32; others have reported that
breastfeeding was not related to postpartum relapses, and
relapse rates before or during pregnancy were the main factors
that determined the risk of relapse during the postpartum
period.33 The potential protective effect of breastfeeding in
MS prognosis may be at least partially explained by selection
bias because women with milder disease activity and less
disability would be more prone to breastfeed their children
compared to patients with more active disease.28 Again,
controlling for previously known prognostic factors and per-
forming time-dependent analyses may help to avoid selection
bias and weight accurately the real effect of breastfeeding.
Our study has 2 important strengths. The first strength is the
characteristics and number of patients included in this report.
These female participants are part of a prospective, open CIS
cohort with a long follow-up, and they are evaluated on
a regular basis. Demographic, clinical, MRI, and treatment
information is recorded prospectively under a prespecified
protocol. These high-quality data allow us to perform adjusted
analyses for possible confounding factors.
The second strength lies in the statistical analyses used; with
our time-dependent approach, the HR reflects the effect of
pregnancy from the moment in which the patient becomes
pregnant instead of treating it like a baseline covariate. In
addition, breastfeeding was modeled analogously. In time-
fixed models one assumes that the exposure (in this case,
pregnancy or breastfeeding) is present since the beginning of
follow-up until the end of the course of the patient. Thus,
ignoring the time-dependent nature of an exposure could lead
to time-dependent bias.34 A propensity score over the preg-
nancy status was performed to avoid a probable selection bias.
For instance, a woman with a mild progression of the disease
could be more likely to be pregnant than a woman with
a more aggressive course. This approach has been performed
in other previous studies.35 However, in our study we have
considered not only clinical variables for the multivariate
analysis but biological (oligoclonal bands) and MRI data, and
both factors are known to be important at the time to predict
the course of MS.4
The results of this study provide us with useful information for
women with MS regarding reproductive counseling. The
main message is that the prognosis of MS will not be signif-
icantly affected by pregnancy once all other variables are
considered. In this regard, the clinical activity, MRI findings,
Neurology.org/N Neurology | Volume 92, Number 13 | March 26, 2019 e1513
and early initiation of treatment are the most important
prognostic factors that should be considered when addressing
reproductive decisions.
It is known that the risk of MS is multifactorial, and hormones
may play an important role in the risk of the disease, but this
effect may be diminished once the disease is established.
Future studies considering the exact time of menarche and the
characteristics of breastfeeding in the overall disease course
are required to further establish the association between re-
productive background and MS prognosis.
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